Effect of alpha-lipoic acid on asymmetric dimethylarginine and disability in multiple sclerosis patients
A randomized clinical trial
Keywords:
Lipoic acid, Multiple sclerosis, Inflammation, Asymmetric dimethylarginineAbstract
Background: Multiple Sclerosis (MS) is an inflammatory and demyelinating disease of the central nervous system. Oxidative stress plays a major role in the onset and progression of MS. Asymmetric dimethylarginine (ADMA) formation is dependent on oxidative stress status.
Objective: We examined whether alpha-lipoic acid (ALA) as a potent antioxidant could improve the Expanded Disability Status Scale (EDSS) and decrease plasma level of ADMA in multiple sclerosis patients.
Methods: In a randomized, double-blinded clinical trial conducted at Sina Hospital in Tehran, Iran, from September 2009 to July 2011, 24 patients with relapsing-remitting MS were divided into a treatment group receiving ALA (1200mg/day) for 12 weeks and a control group receiving placebo. Then patients’ EDSS and Plasma levels of ADMA were measured at baseline and 12 weeks later. Statistical analysis was done by SPSS software version 16 using the K-S test, Chi square, Mann–Whitney U-test and Wilcoxon test.
Results: The plasma levels of ADMA in the intervention group were decreased significantly (p=0.04). Also, no patient had increased EDSS score in the supplement group, where 2 out of 12 patients in the placebo group experienced so. Comparing the serum level of ADMA between the two groups failed to show any significant change in the supplement group compared with the control group.
Conclusion: Considering that ADMA is produced by oxidative stress in MS patients and leads to increase of inflammation, ALA may have the potential of beneficial effects in them, in part, by decreasing the plasma level of ADMA and stopping progression.
Trial registration: The trial was registered at the Iranian Registry of Clinical Trials (http://www.irct.ir) with the Irct ID: No. IRCT138812222602N2.
Funding: The authors received no financial support for the research, authorship, and/or publication of this article.
References
Babaloo Z, Babaie F, Farhoodi M, Aliparasti MR, Baradaran B, Almasi S, et al. Interleukin-17A and
Interleukin-17F mRNA Expressions in Peripheral Blood Mononuclear Cells of Patients with Multiple
Sclerosis. Iran J Immunol. 2010; 7(4): 202-9. doi: IJIv7i4A1. PMID: 21189442.
Lassmann H, Brück W, Lucchinetti C. Heterogeneity of multiple sclerosis pathogenesis: implications for
diagnosis and therapy. Trends Mol Med. 2001, 7(3): 115-21. doi: 10.1016/S1471-4914(00)01909-2. PMID:
Sandoo A, Dimitroulas T, Hodson J, Smith JP, Douglas KM, Kitas GD. Cumulative inflammation
associates with asymmetric dimethylarginine in rheumatoid arthritis: a 6 year follow-up study.
Rheumatology (Oxford). 2015; 54(7): 1145-52. doi: 10.1093/rheumatology/keu349. PMID: 25187642.
Ghasemi M, Fatemi A. Pathologic role of glial nitric oxide in adult and pediatric neuroinflammatory
diseases. Neurosci Biobehav Rev. 2014; 45: 168-82. doi: 10.1016/j.neubiorev.2014.06.002. PMID:
Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain
Pathol. 1999; 9(1): 69-92. doi: 10.1111/j.1750-3639.1999.tb00212.x. PMID: 9989453.
Bö L, Dawson TM, Wesselingh S, Möurk S, Choi S, Kong PA, et al. Induction of nitric oxide synthase in
demyelinating regions of multiple sclerosis brains. Ann Neurol. 1994; 36(5): 778-86. doi:
1002/ana.410360515. PMID: 7526776.
Bagasra O, Michaels FH, Zheng YM, Bobroski LE, Spitsin SV, Fu ZF, et al. Activation of the inducible
form of nitric oxide synthase in the brains of patients with multiple sclerosis. Proc Natl Acad Sci U S A.
; 92(26): 12041-5. doi: 10.1073/pnas.92.26.12041. PMID: 8618840, PMCID: PMC40292.
Endoh M, Maiese K, Wagner J. Expression of the inducible form of nitric oxide synthase by reactive
astrocytes after transient global ischemia. Brain Res. 1994; 651(1-2): 92-100. doi: 10.1016/0006- 8993(94)90683-1. PMID: 7522935.
Lin RF, Lin TS, Tilton RG, Cross AH. Nitric oxide localized to spinal cords of mice with experimental
allergic encephalomyelitis: an electron paramagnetic resonance study. J Exp Med. 1993; 178(2): 643-8.
doi: 10.1084/jem.178.2.643. PMID: 8393479, PMCID: PMC2191106.
Gilgun-Sherki Y, Melamed E, Offen D. The role of oxidative stress in the pathogenesis of multiple
sclerosis: the need for effective antioxidant therapy. J Neurol. 2004; 251(3): 261-8. doi: 10.1007/s00415- 004-0348-9. PMID: 15015004.
Luo Y, Yue W, Quan X, Wang Y, Zhao B, Lu Z. Asymmetric dimethylarginine exacerbates Aβ-induced
toxicity and oxidative stress in human cell and Caenorhabditis elegans models of Alzheimer disease. Free
Radic Biol Med. 2015; 79: 117-26. doi: 10.1016/j.freeradbiomed.2014.12.002. PMID: 25499850.
Moini H, Packer L, Saris NE. Antioxidant and prooxidant activities of α-lipoic acid and dihydrolipoic acid.
Toxicol Appl Pharmacol. 2002; 182(1): 84-90. doi:10.1006/taap.2002.9437. PMID: 12127266.
Khalili M, Eghtesadi S, Mirshafiey A, Eskandari G, Sanoobar M, Sahraian MA, et al. Effect of lipoic acid
consumption on oxidative stress among multiple sclerosis patients: A randomized controlled clinical trial.
Nutr Neurosci. 2014; 17(1): 16-20. doi: 10.1179/1476830513Y.0000000060. PMID: 23485514.
Yadav V, Marracci G, Lovera J, Woodward W, Bogardus K, Marquardt W, et al. Lipoic acid in multiple
sclerosis: a pilot study. Mult Scler. 2005; 11(2): 159-65. doi: 10.1191/1352458505ms1143oa. PMID:
Salinthone S, Yadav V, Bourdette DN, Carr DW. Lipoic acid: a novel therapeutic approach for multiple
sclerosis and other chronic inflammatory diseases of the CNS. Endocr Metab Immune Disord Drug
Targets. 2008; 8(2): 132-42. doi: 10.2174/187153008784534303. PMID: 18537699.
Chang JW, Lee EK, Kim TH, Min WK, Chun S, Lee KU, et al. Effects of α-lipoic acid on the plasma levels
of asymmetric dimethylarginine in diabetic end-stage renal disease patients on hemodialysis: a pilot study.
Am J Nephrol. 2007; 27(1): 70-4. doi: 10.1159/000099035. PMID: 17259696.
Mitrovic B, Ignarro LJ, Vinters HV, Akers MA, Schmid I, Uittenbogaart C, et al. Nitric oxide induces
necrotic but not apoptotic cell death in oligodendrocytes. Neuroscience. 1995; 65(2): 531-9. doi:
1016/0306-4522(94)00491-M. PMID: 7777166.
Smith KJ, Lassmann H. The role of nitric oxide in multiple sclerosis. Lancet Neurol. 2002; 1(4): 232-41.
doi: 10.1016/S1474-4422(02)00102-3. PMID: 12849456.
Polman CH, Reingold SC, Banwell B, Clanet M, Cohen JA, Filippi M, et al. Diagnostic criteria for
multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol. 2011; 69(2): 292-302. doi:
1002/ana.22366. PMID: 21387374, PMCID: PMC3084507.
Pi J, Kumagai Y, Sun G, Shimojo N. Improved method for simultaneous determination of L-arginine and
its mono-and dimethylated metabolites in biological samples by high-performance liquid chromatography.
J Chromatogr B Biomed Sci Appl. 2000; 742(1): 199-203. doi: 10.1016/S0378-4347(00)00145-6. PMID:
Koprowski H, Zheng YM, Heber-Katz E, Fraser N, Rorke L, Fu ZF, et al. In vivo expression of inducible
nitric oxide synthase in experimentally induced neurologic diseases. Proc Natl Acad Sci U S A. 1993;
(7): 3024-7. doi: 10.1073/pnas.90.7.3024. PMID: 7681993, PMCID: PMC46229.
Johnson AW, Land JM, Thompson EJ, Bolaños JP, Clark JB, Heales SJ. Evidence for increased nitric
oxide production in multiple sclerosis. J Neurol Neurosurg Psychiatry. 1995; 58(1): 107. doi:
1136/jnnp.58.1.107. PMID: 7823050, PMCID: PMC1073282.
Stojanovic I, Vojinovic S, Ljubisavljevic S, Pavlovic R, Basic J, Pavlovic D, et al. INF-β1b therapy
modulates l-arginine and nitric oxide metabolism in patients with relapse remittent multiple sclerosis. J
Neurol Sci. 2012; 323(1-2): 187-92. doi: 10.1016/j.jns.2012.09.014. PMID: 23026532.
Conte C, Floridi E, Galli F, Aisa C, Floridi A. A new method for the liquid chromatography analysis of
methylated arginines in biological fluids and tissues by o-phthaldialdehyde postcolumn derivatization. Anal
Biochem. 2005; 338(2): 347-9. doi: 10.1016/j.ab.2004.11.018. PMID: 15745758.
Owczarek D, Cibor D, Mach T. Asymmetric dimethylarginine (ADMA), symmetric dimethylarginine
(SDMA), arginine, and 8‐iso‐prostaglandin F2α (8‐iso‐PGF2α) level in patients with inflammatory
bowel diseases. Inflamm Bowel Dis. 2010; 16(1): 52-7. doi: 10.1002/ibd.20994. PMID: 19575355.
Schreibelt G, Musters RJ, Reijerkerk A, de Groot LR, van der Pol SM, Hendrikx EM, et al. Lipoic acid
affects cellular migration into the central nervous system and stabilizes blood-brain barrier integrity. J
Immunol. 2006; 177(4): 2630-7. doi: 10.4049/jimmunol.177.4.2630. PMID: 16888025.
Marracci GH, McKeon GP, Marquardt WE, Winter RW, Riscoe MK, Bourdette DN. Alpha lipoic acid
inhibits human T-cell migration: implications for multiple sclerosis. J Neurosci Res. 2004; 78(3): 362-70. doi: 10.1002/jnr.20255. PMID: 15389837.
Chaudhary P, Marracci GH, Bourdette DN. Lipoic acid inhibits expression of ICAM-1 and VCAM-1 by
CNS endothelial cells and T cell migration into the spinal cord in experimental autoimmune
encephalomyelitis. J Neuroimmunol. 2006; 175(1-2): 87-96. doi: 10.1016/j.jneuroim.2006.03.007. PMID:
Khalili M, Azimi A, Izadi V, Eghtesadi S, Mirshafiey A, Sahraian MA, et al. Does Lipoic Acid
Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo- Controlled, Randomized Clinical Trial. Neuroimmunomodulation. 2014; 21(6): 291-6. doi:
1159/000356145. PMID: 24821457.
Mittermayer F, Pleiner J, Francesconi M, Wolzt M. Treatment with α-lipoic acid reduces asymmetric
dimethylarginine in patients with type 2 diabetes mellitus. Transl Res. 2010; 155(1): 6-9. doi:
1016/j.trsl.2009.08.004. PMID: 20004356.
Vallance P, Leiper J. Cardiovascular biology of the asymmetric dimethylarginine: dimethylarginine
dimethylaminohydrolase pathway. Arterioscler Thromb Vasc Biol. 2004; 24(6): 1023-30. doi:
1161/01.ATV.0000128897.54893.26. PMID: 15105281.
Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, et al. Impaired nitric oxide synthase
pathway in diabetes mellitus role of asymmetric dimethylarginine and dimethylarginine
dimethylaminohydrolase. Circulation. 2002; 106(8): 987-92. doi: 10.1161/01.CIR.0000027109.14149.67.
PMID: 12186805.
Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide
synthases. Cardiovasc Res. 1999; 43(3): 542-8. doi: 10.1016/S0008-6363(99)00162-5. PMID: 10690326
Published
Issue
Section
License
Copyright (c) 2020 KNOWLEDGE KINGDOM PUBLISHING
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
